SCHEMBL3237802

SCHEMBL3237802

Cc1c(Cl)cccc1C(=O)NC(c1ccccc1)C1(N(C)C)CCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 9/20 0.48
UTS2R Q9UKP6 2/20 0.47
TAS1R3 Q7RTX0 2/20 0.42
TAS1R1 Q7RTX1 2/20 0.42
TAS1R2 Q8TE23 2/20 0.42
HDAC4 P56524 1/20 0.40
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
MT-CO2 P00403 1/20 0.39
TTR P02766 1/20 0.39
PLA2G1B P04054 1/20 0.39
CYP1A2 P05177 1/20 0.39
PGR P06401 1/20 0.39
CYP3A4 P08684 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
ADORA3 P0DMS8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3244891 0.90 SLC6A9 (0.59) SLC6A9TAS1R3TAS1R1TAS1R2GPR139
SCHEMBL3232935 0.88 SLC6A9 (0.47) SLC6A9UTS2RTAS1R3TAS1R1TAS1R2
SCHEMBL3230692 0.86 SLC6A9 (0.48) SLC6A9UTS2RTAS1R3TAS1R1TAS1R2
SCHEMBL3242235 0.86 ALDH1A1 (0.43) SLC6A9LMNAKMT2AMEN1CYP1A2
SCHEMBL3238085 0.86 TAS1R3 (0.41) SLC6A9TAS1R3TAS1R1TAS1R2HDAC4
SCHEMBL3240614 0.86 SLC6A9 (0.56) SLC6A9
SCHEMBL3234711 0.85 SLC6A9 (0.40) SLC6A9KMT2AMEN1SMN1; SMN2
SCHEMBL3239398 0.85 SLC6A9 (0.55) SLC6A9
SCHEMBL3237287 0.84 SLC6A9 (0.45) SLC6A9UTS2RLMNACYP1A2HPGD
SCHEMBL3236079 0.84 SLC6A9 (0.51) SLC6A9UTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 SLC6A9 13/4885UTS2R 3013/4885TAS1R3 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.